|
Drug Topics
Community Pharmacists' Report
DrugTopics.com
November 15, 2011 |
AHA MEETING COVERAGE
Rivaroxaban (Xarelto, Janssen Pharmaceuticals), an oral anticoagulant that directly inhibits factor Xa, reduced the risk of death, myocardial infarction, and stroke in patients with acute coronary syndrome, according to a report presented at the American Heart Association's Scientific Sessions 2011, Orlando, Fla. » More
|
Consultation with non-specialist pharmacists did not improve rates of hospitalization or death for patients with left ventricular systolic dysfunction (heart failure), according to the results of a large-scale, long-term prospective randomized trial conducted by the National Health Service and reported at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla. » More
|
ADVERTISEMENT
Resource Center: Oral Anticoagulation in Atrial Fibrillation
Atrial fibrillation afflicts more than 2.3 million persons in the United States and is expected to increase 2.5-fold by 2050. To find risk stratifying tools and articles on emerging oral anticoagulant therapies,
click here. |
CONTINUING EDUCATION
In carrying out Risk Evaluation and Mitigation Strategies associated with long-acting opioids, the pharmacist plays a multidimensional role in this effort, which includes educating patients, prescribers, and the community at large, being vigilant to signs of overprescribing or abuse, and recognizing the biopsychosocial factors that put pain patients at risk for substance abuse. » Click here to login and take the exams. |
IMMUNIZATIONS
The California Pharmacists Association (CPhA) and PrescribeWellness, a healthcare digital communication solutions provider, are partnering on the “One Million More” flu shot campaign to increase the yearly influenza vaccination rate. » More |
Survey
a) Yes, it will definitely make a difference to the prescription drug shortages.
b) Yes, but it will take more than the order to fix the prescription drug shortages.
c) No, Congress should be enacting legislation to fix the prescription drug shortages.
d) No, the order will do little to help the prescription drug shortages.
Respond here and see what your colleagues think too.
Want to see the results of our last survey about the implications of the possible Express Scripts/Medco merger? Click here.
|
FDA ACTIONS
FDA has approved cetuximab (Erbitux, Bristol-Myers Squibb) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer. » More |
CLINICAL NEWS
Merck has announced in a prepared statement that its contraceptive implant (Nexplanon) is now available in the United States. » More |
TECHNOLOGY
About 11% of U.S. adult cell phone users downloaded an application (or app) that “helped them track or manage their health” in August 2011, according to a survey by Pew Research Centers’ Internet & American Life Project. » More |
OTC PRODUCTS
In this section we showcase products and product news that ran up against space limitations or fell outside the parameters of recently featured categories in the print edition. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|